Boundless Bio to Join Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio, a clinical-stage oncology company listed on Nasdaq under the ticker BOLD, focuses on studying extrachromosomal DNA (ecDNA) biology to develop groundbreaking treatments for patients with oncogene-amplified cancers, which have been difficult to treat. The company's President and CEO, Zachary Hornby, along with CFO Jami Rubin, will be featured in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is set for Wednesday, June 12, in Miami, FL, at 3:20 p.m. ET. The discussion will be available for live streaming and later as an archived webcast on Boundless Bio’s website under the “Events & Presentations” section.

Boundless Bio is pioneering a novel approach in cancer treatment by focusing on the significant problem of oncogene amplification through targeting extrachromosomal DNA (ecDNA). Oncogene amplification is seen in over 14% of cancer patients and leads to aggressive tumor growth. The company has developed the first ecDNA-directed therapy (ecDTx) named BBI-355. BBI-355 is an oral inhibitor of checkpoint kinase 1 (CHK1) currently being tested in a Phase 1/2 clinical trial to assess its effectiveness in patients with oncogene-amplified cancers.

In addition to BBI-355, Boundless Bio is also developing another ecDTx, BBI-825. This therapy targets ribonucleotide reductase (RNR) and is likewise being evaluated in a Phase 1/2 clinical trial aimed at treating cancers with resistance gene amplifications. These efforts are part of Boundless Bio's mission to offer new treatments for tough-to-treat cancers, providing hope for patients who have limited options.

The company leverages its proprietary Spyglass platform to advance additional programs through preclinical development and discovery stages. This platform is integral to Boundless Bio’s strategy, enabling the identification and development of novel therapies that target ecDNA and its associated oncogene amplifications.

Boundless Bio is based in San Diego, California, and continues to push the boundaries of cancer research, aiming to translate their discoveries into real-world clinical benefits for patients struggling with oncogene-amplified tumors.